-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Commentary | Li Maomao (West China Second Hospital) Medical Medicine The new crown pneumonia (COVID-19) caused by the new crown virus (SARS-CoV-2) is still raging around the world, and the number of confirmed infections has exceeded 110 million.
Existing studies have shown that the Ig antibody that recognizes the SARS-CoV-2 spike protein (S protein) has the ability to neutralize the virus and is a key molecule for the host to establish immune protection.
The level of neutralizing antibody is important for predicting the recovery period of COVID-19 The protection of patients is also crucial.
Although the early immune response after SARS-CoV-2 infection has been fully described, and whether convalescent patients and whether they will re-infect after being vaccinated with the new crown vaccine has also received more and more attention, there is still a lack of neutralization in the body of convalescent patients.
Long-term monitoring of antibody levels.
A comprehensive understanding of the dynamic changes of antibody levels after infection will be the key to understanding disease pathogenesis, risk assessment of susceptible populations, evaluation of treatment methods, and vaccine development.
On January 30, 2021, Med magazine published an online work by the Julià Blanco team titled "Stable neutralizing antibody levels six months after mild and severe COVID-19 episode".
The author monitored asymptomatic, mild and severe patients with SARS-CoV-2 infection for up to 6 months and found that although the level of neutralizing antibodies continued to decline after infection, the ability of the serum to neutralize the virus was at least maintained 6 months.
▲Long press the picture to identify the QR code to read the original text.
In order to study the changes of the neutralizing antibody in SARS-CoV-2 infected persons, the researchers used the SARS-CoV-2 pseudovirus neutralization experiment (using the HIV virus as the skeleton, coated with SARS) -Spike protein of Cov-2) to evaluate the neutralizing activity of the infected person’s serum to the virus, and use ELISA to determine the titers of neutralizing antibodies anti-RBD and anti-S2 IgG.
210 SARS-CoV-2 infected persons were tested 242 days of monitoring (including 106 mild or asymptomatic infections and 104 hospitalized patients).
The results showed that whether it was a mild or asymptomatic infection or a severely ill patient, the levels of neutralizing antibodies anti-RBD and anti-S2 IgG continued to decline within 6 months after infection (Figure 1).
▲Figure 1.
The levels of neutralizing antibodies anti-RBD and anti-S2 IgG in patients with new coronary pneumonia 6 months after infection Although the levels of neutralizing antibodies continue to decrease after infection, the author found that the serum of patients with mild or asymptomatic infections The neutralizing ability of the virus did not decrease significantly at 6 months (Figure 2A).
The ability of inpatients' serum to neutralize the virus showed a two-stage decline after infection: a rapid decline after 30 days of symptoms, and a markedly slower decline after the 80th day (Figure 2B).
The neutralizing ability of the serum of hospitalized patients is significantly higher than that of patients with mild or asymptomatic infection, and it is speculated that they have a lower risk of re-infection.
▲Figure 2.
Neutralizing ability of serum in patients with new coronary pneumonia 6 months after infection The author pointed out that the current immunological evidence after SARS-CoV-2 infection shows that the neutralizing ability of serum is stable, which is the basis for establishment Viral infection or vaccine-mediated herd immunity provides an optimistic outlook.
Nevertheless, according to the long-term data of the coronavirus, the factors that lead to the weakening of antibody neutralization are uncertain.
Further analysis of larger populations is needed to assess the protective immune effect of neutralizing antibodies on virus re-exposure.
The research results of related paper information are published in the Med journal under Cell Press.
Click "Read Full Text" or scan the QR code below to view the paper. ▌Paper title: Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes▌Paper URL: https://▌DOI: https: //doi.
org/10.
1016/j.
medj.
2021.
01.
005▲Long press the picture to identify the QR code to read the original recommendation Reading the exclusive recommendation | 2020 high-interest articles recommended by the editor-in-chief of Med▲
Existing studies have shown that the Ig antibody that recognizes the SARS-CoV-2 spike protein (S protein) has the ability to neutralize the virus and is a key molecule for the host to establish immune protection.
The level of neutralizing antibody is important for predicting the recovery period of COVID-19 The protection of patients is also crucial.
Although the early immune response after SARS-CoV-2 infection has been fully described, and whether convalescent patients and whether they will re-infect after being vaccinated with the new crown vaccine has also received more and more attention, there is still a lack of neutralization in the body of convalescent patients.
Long-term monitoring of antibody levels.
A comprehensive understanding of the dynamic changes of antibody levels after infection will be the key to understanding disease pathogenesis, risk assessment of susceptible populations, evaluation of treatment methods, and vaccine development.
On January 30, 2021, Med magazine published an online work by the Julià Blanco team titled "Stable neutralizing antibody levels six months after mild and severe COVID-19 episode".
The author monitored asymptomatic, mild and severe patients with SARS-CoV-2 infection for up to 6 months and found that although the level of neutralizing antibodies continued to decline after infection, the ability of the serum to neutralize the virus was at least maintained 6 months.
▲Long press the picture to identify the QR code to read the original text.
In order to study the changes of the neutralizing antibody in SARS-CoV-2 infected persons, the researchers used the SARS-CoV-2 pseudovirus neutralization experiment (using the HIV virus as the skeleton, coated with SARS) -Spike protein of Cov-2) to evaluate the neutralizing activity of the infected person’s serum to the virus, and use ELISA to determine the titers of neutralizing antibodies anti-RBD and anti-S2 IgG.
210 SARS-CoV-2 infected persons were tested 242 days of monitoring (including 106 mild or asymptomatic infections and 104 hospitalized patients).
The results showed that whether it was a mild or asymptomatic infection or a severely ill patient, the levels of neutralizing antibodies anti-RBD and anti-S2 IgG continued to decline within 6 months after infection (Figure 1).
▲Figure 1.
The levels of neutralizing antibodies anti-RBD and anti-S2 IgG in patients with new coronary pneumonia 6 months after infection Although the levels of neutralizing antibodies continue to decrease after infection, the author found that the serum of patients with mild or asymptomatic infections The neutralizing ability of the virus did not decrease significantly at 6 months (Figure 2A).
The ability of inpatients' serum to neutralize the virus showed a two-stage decline after infection: a rapid decline after 30 days of symptoms, and a markedly slower decline after the 80th day (Figure 2B).
The neutralizing ability of the serum of hospitalized patients is significantly higher than that of patients with mild or asymptomatic infection, and it is speculated that they have a lower risk of re-infection.
▲Figure 2.
Neutralizing ability of serum in patients with new coronary pneumonia 6 months after infection The author pointed out that the current immunological evidence after SARS-CoV-2 infection shows that the neutralizing ability of serum is stable, which is the basis for establishment Viral infection or vaccine-mediated herd immunity provides an optimistic outlook.
Nevertheless, according to the long-term data of the coronavirus, the factors that lead to the weakening of antibody neutralization are uncertain.
Further analysis of larger populations is needed to assess the protective immune effect of neutralizing antibodies on virus re-exposure.
The research results of related paper information are published in the Med journal under Cell Press.
Click "Read Full Text" or scan the QR code below to view the paper. ▌Paper title: Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes▌Paper URL: https://▌DOI: https: //doi.
org/10.
1016/j.
medj.
2021.
01.
005▲Long press the picture to identify the QR code to read the original recommendation Reading the exclusive recommendation | 2020 high-interest articles recommended by the editor-in-chief of Med▲
